Ovarian epithelial cancer

Active Research Protocols

  1. 00-C-0018 – A Pilot Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile Associated with Relapse
  2. 04-C-0232 – A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
  3. 07-C-0061 – Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the VEGFR2 Inhibitor, ZD6474 (Vandetanib) in Women with Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  4. 11-C-0022 – A Pharmacokinetic/Pharmacodynamic Study with a Phase I Run-In with a PARP Inhibitor (Olaparib) in Combination with Carboplatin for Refractory or Recurrent Women's Cancers
  5. 12-C-0191 – Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014